Eric Gulve, Ph.D. has been the President of BioGenerator since 2007. Dr. Gulve currently sits on the Board of Directors of five portfolio companies. Prior to joining BioGenerator, Dr. Gulve spent 14 years in the pharmaceutical industry focused on drug discovery research. From 2003 – 2007 he held various roles in local and global leadership teams in Cardiovascular research at Pfizer, and led laboratories working in the areas of thrombosis, hypertension, and metabolic disease. From 2000 – 2003, Dr. Gulve was Associate Director of the Cardiovascular & Metabolic Diseases research group at Pharmacia Corporation, prior to Pharmacia's acquisition by Pfizer. From 1994 – 2000 he directed laboratory groups and served on leadership teams within G.D. Searle's Cardiovascular drug discovery research group, where he played a key role in initiating and leading the company's first diabetes research program. Dr. Gulve received an A.B. in Chemistry from Occidental College (Los Angeles) and a Ph.D. in Physiology from Harvard University. He served as a post-doctoral fellow and subsequently on the research faculty at Washington University School of Medicine, where his research focused on skeletal muscle metabolism and the molecular mechanisms which contribute to the beneficial effects of exercise in diabetes and other states characterized by defective glucose metabolism. Dr. Gulve has published over 40 peer-reviewed articles and has contributed to several book chapters and review articlesNew Paragraph